[Systemic therapy of metastatic bladder cancer.]

about

Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status.

P2860

Q38715263-41077489-E8B3-4E84-BA70-0EAC99E6E89C

P2860

[Systemic therapy of metastatic bladder cancer.]

Item

http://www.wikidata.org/entity/Q44419809

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

[Systemic therapy of metastatic bladder cancer.]

@en

[Systemic therapy of metastatic bladder cancer.]

@nl

type

Item

label

[Systemic therapy of metastatic bladder cancer.]

@en

[Systemic therapy of metastatic bladder cancer.]

@nl

prefLabel

[Systemic therapy of metastatic bladder cancer.]

@en

[Systemic therapy of metastatic bladder cancer.]

@nl

P1476

[Systemic therapy of metastatic bladder cancer.]

@en

P2093

A S Merseburger

http://www.w3.org/2001/XMLSchema#string

M Retz

http://www.w3.org/2001/XMLSchema#string

M W Kramer

http://www.w3.org/2001/XMLSchema#string

S C Schmid

http://www.w3.org/2001/XMLSchema#string

P2860

Genome sequencing identifies a basis for everolimus sensitivity

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy.

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

Phase II study of everolimus in metastatic urothelial cancer.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Antitumor activity of vinflunine: effector pathways and potential for synergies.

Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

P31

scholarly article

P356

10.1007/S00120-013-3250-1

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24121473

http://www.w3.org/2001/XMLSchema#string

[Systemic therapy of metastatic bladder cancer.]

about

P2860

P2860

[Systemic therapy of metastatic bladder cancer.]

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698